SCHEMBL5714486

SCHEMBL5714486

O=C(Oc1ccc(N2C(=O)C3CCCCC3C2=O)cn1)N1CCN(CCc2cccnc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
DRD2 P14416 4/20 0.39
HTR1A P08908 3/20 0.39
CHRM3 P20309 2/20 0.39
ALDH1A1 P00352 2/20 0.38
ALOX15 P16050 1/20 0.38
OPRM1 P35372 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
DRD4 P21917 1/20 0.36
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714760 0.95 KDM4E (0.45) KDM4EKMT2AL3MBTL1HTR1ACHRM3
SCHEMBL5714634 0.91 KDM4E (0.47) KDM4EKMT2AL3MBTL1ALDH1A1POLB
SCHEMBL5715222 0.85 THRB (0.46) KDM4EKMT2AL3MBTL1ALDH1A1OPRM1
SCHEMBL5714680 0.83 KMT2A (0.36) KDM4EKMT2AL3MBTL1DRD2CHRM3
SCHEMBL5714337 0.83 ALDH1A1 (0.42) KMT2AL3MBTL1ALDH1A1POLBHPGD
SCHEMBL6102575 0.83 HTR1A (0.39) KDM4EDRD2HTR1AALDH1A1ALOX15
SCHEMBL5714854 0.82 THRB (0.41) KDM4EKMT2AL3MBTL1CHRM3ALDH1A1
SCHEMBL5715472 0.82 ALDH1A1 (0.36) KMT2AL3MBTL1CHRM3ALDH1A1HRH3
SCHEMBL5714590 0.81 MGLL (0.37) KDM4EKMT2AL3MBTL1ALDH1A1HRH3
SCHEMBL5714200 0.81 KCNH2 (0.39) KDM4EKMT2AL3MBTL1ALDH1A1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL KDM4E 1090/4885KMT2A 1677/4885L3MBTL1 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.